Hojda Silvana Elena, Chis Irina Camelia, Clichici Simona
Department of Physiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Number 1-3, Clinicilor Street, RO-400023 Cluj-Napoca, Romania.
Diagnostics (Basel). 2022 Dec 3;12(12):3033. doi: 10.3390/diagnostics12123033.
Pulmonary arterial hypertension (PAH) is a severe medical condition characterized by elevated pulmonary vascular resistance (PVR), right ventricular (RV) failure, and death in the absence of appropriate treatment. The progression and prognosis are strictly related to the etiology, biochemical parameters, and treatment response. The gold-standard test remains right-sided heart catheterization, but dynamic monitoring of systolic pressure in the pulmonary artery is performed using echocardiography. However, simple and easily accessible non-invasive assays are also required in order to monitor this pathology. In addition, research in this area is in continuous development. In recent years, more and more biomarkers have been studied and included in clinical guidelines. These biomarkers can be categorized based on their associations with inflammation, endothelial cell dysfunction, cardiac fibrosis, oxidative stress, and metabolic disorders. Moreover, biomarkers can be easily detected in blood and urine and correlated with disease severity, playing an important role in diagnosis, prognosis, and disease progression.
肺动脉高压（PAH）是一种严重的病症，其特征为肺血管阻力（PVR）升高、右心室（RV）衰竭，若未得到适当治疗则会导致死亡。疾病的进展和预后与病因、生化参数及治疗反应密切相关。金标准检测仍是右心导管检查，但使用超声心动图可对肺动脉收缩压进行动态监测。然而，为了监测这种病症，还需要简单且易于获取的非侵入性检测方法。此外，该领域的研究也在不断发展。近年来，越来越多的生物标志物得到研究并被纳入临床指南。这些生物标志物可根据其与炎症、内皮细胞功能障碍、心脏纤维化、氧化应激和代谢紊乱的关联进行分类。此外，生物标志物在血液和尿液中易于检测，且与疾病严重程度相关，在诊断、预后和疾病进展中发挥着重要作用。
